January 2025

Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn’s disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat through study

Lancet 2024;404:2423–36 doi: 10.1016/S0140-6736(24)01762-8

Ferrante et al. conducted a phase 3 trial evaluating the efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn’s disease. The study demonstrated that mirikizumab significantly improved clinical and endoscopic outcomes compared with placebo at week 52, with a favourable safety profile and tolerable adverse events.

Keywords:

Integrated safety analysis of tofacitinib from Phase 2 and 3 trials of patients with ankylosing spondylitis

Journal Reference: Adv Rheumatol. 2024 Dec 18;64:87 doi: 10.1186/s42358-024-00402-x

Deodhar et al. conducted a pooled analysis of Phase 2 and 3 RCT data to assess the safety of tofacitinib in AS. The results showed that tofacitinib 5 mg BID had a tolerable safety profile over 48 weeks, consistent with its use in other inflammatory conditions such as RA and PsA.

Keywords:

December 2024

Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study

RMD Open 2024;12:e004476 doi: 10.1136/rmdopen-2024-004476

Buch et al. demonstrated that filgotinib sustained its efficacy in rheumatoid arthritis patients through Wk156 in the FINCH 4 long-term extension study, showing stable safety profiles. The study reported high ACR response rates and remission based on Boolean criteria, underlining filgotinib's potential for extended clinical benefits.

Keywords:

November 2024

Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial

Lancet. 2024;9:981–96 doi: 10.1016/S2468-1253(24)00200-0

Choy et al. investigated the efficacy and safety of intensified versus standard infliximab dosing for steroid-refractory acute severe ulcerative colitis (ASUC). The study found that a first dose of 10mg/kg infliximab was not superior to the standard 5mg/kg dose in achieving clinical response by Day 7. Earlier responses were noted with dose intensification, but no significant differences were observed in remission, colectomy rates, or safety profiles by Month 3.

Keywords:

Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexate

Rheumatology, 2024. Epub ahead of print doi: 10.1093/rheumatology/keae486

Buch et al. evaluated the efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and inadequate response to methotrexate in the FINCH 1 study. At     Wk 12, ACR20 response rates were significantly higher with filgotinib 200 mg (77.9%) and 100 mg (67.8%) compared to placebo (43.8%). Safety profiles for both filgotinib doses were similar to adalimumab.

Keywords:

October 2024

Efficacy and safety of intravenous secukinumab for the treatment of active psoriatic arthritis: Results from the randomized, placebo-controlled Phase III INVIGORATE-2 study

Arthritis Rheumatol 2024 doi: 10.1002/art.42997

IV secukinumab provided rapid and sustained improvements in disease signs and symptoms at Week 16 and through 52 weeks. Kivitz et al. evaluated the long-term efficacy, safety, and tolerability of IV secukinumab in patients with active PsA.

Keywords:

Efficacy and safety of current therapies for difficult-to-treat rheumatoid arthritis: a systematic review and network meta-analysis

Journal of Translational Medicine 2024;22:795

Su et al. conducted a comprehensive systematic review and network meta-analysis to assess the efficacy and safety of therapies for difficult-to-treat (D2T) RA. They found that tocilizumab and rituximab had superior efficacy and safety profiles, with 8mg every 4 weeks of tocilizumab identified as the optimal therapeutic dose.

Keywords:

September 2024

A comparison of the safety and efficacy of tapinarof and roflumilast topical therapies in the management of mild-to-moderate plaque psoriasis

Skin Res Technol. 2024 Sep;30:e70041 doi: 10.1111/srt.70041

Ghani et al. compared the efficacy and safety profiles of tapinarof and roflumilast for treating mild-to-moderate plaque psoriasis. Both therapies showed robust efficacy and were well-tolerated, with low rates of adverse events. Tapinarof exhibited marginally higher efficacy in PASI scores compared to roflumilast.

Keywords:

Efficacy and safety of etrasimod in patients with moderately to severely active isolated proctitis: Results from the Phase 3 ELEVATE UC clinical programme

JJC 2024;18;391(3):2170 82. DOI 10.1093/ecco-jcc/jjae038

Peyrin-Biroulet et al. evaluated the efficacy and safety of etrasimod in patients with moderately to severely active isolated proctitis, demonstrating significant improvement in clinical outcomes compared to placebo. The study reported a favourable safety profile, making etrasimod a viable treatment option for this population.

Keywords:

Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study

Journal Reference: RMD Open. 2024;10:e003918 doi: 10.1136/rmdopen-2023-003918

Fleischmann et al. evaluated the long-term efficacy and safety of upadacitinib in rheumatoid arthritis patients with inadequate response or intolerance to bDMARDs over five years. The study demonstrated that upadacitinib 15 mg and 30 mg were effective in maintaining disease control, with >75% of patients achieving CDAI LDA by week 260. The safety profile remained consistent with no new issues identified.

Keywords: